Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus.

Details

Ressource 1Download: 24652665.pdf (588.10 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_B279E13B1B71
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Transcatheter renal denervation for the treatment of resistant arterial hypertension: the Swiss expert consensus.
Journal
Swiss Medical Weekly
Author(s)
Wuerzner G., Muller O., Erne P., Cook S., Sudano I., Lüscher T.F., Noll G., Kaufmann U., Rickli H., Waeber B., Kaiser C., Sticherling C., Pechère-Bertschi A., Baumgartner I., Jacob A.L., Burnier M., Qanadli S.D., Interventional Radiology
Working group(s)
Swiss Society of Hypertension, Swiss Society of Cardiology, Swiss Society of Angiology, Swiss Society of Cardiovascular
Contributor(s)
Interventional Radiology
ISSN
1424-3997 (Electronic)
ISSN-L
0036-7672
Publication state
Published
Issued date
2014
Volume
144
Pages
w13913
Language
english
Notes
Publication types: Journal Article ; Practice Guideline ; Research Support, Non-U.S. Gov't ; Review Publication Status: epublish
Abstract
Transcatheter (or percutaneous) renal denervation is a novel technique developed for the treatment of resistant hypertension. So far, only one randomised controlled trial has been published, which has shown a reduction of office blood pressure. The Swiss Society of Hypertension, the Swiss Society of Cardiology, The Swiss Society of Angiology and the Swiss Society of Interventional Radiology decided to establish recommendations to practicing physicians and specialists for good clinical practice. The eligibility of patients for transcatheter renal denervation needs (1.) confirmation of truly resistant hypertension, (2.) exclusion of secondary forms of hypertension, (3.) a multidisciplinary decision confirming the eligibility, (4.) facilities that guarantee procedural safety and (5.) a long-term follow-up of the patients, if possible in cooperation with a hypertension specialist. These steps are essential until long-term data on safety and efficacy are available.
Keywords
Antihypertensive Agents/therapeutic use, Arterial Pressure, Consensus, Drug Resistance, Humans, Hypertension/drug therapy, Hypertension/surgery, Kidney/innervation, Patient Selection, Switzerland, Sympathectomy/adverse effects, Sympathectomy/methods
Pubmed
Open Access
Yes
Create date
11/07/2014 12:10
Last modification date
20/08/2019 15:21
Usage data